nodes	percent_of_prediction	percent_of_DWPC	metapath
Enzalutamide—ABCB1—ovarian cancer	0.342	1	CbGaD
Enzalutamide—ABCB1—Topotecan—ovarian cancer	0.0537	0.118	CbGbCtD
Enzalutamide—CYP3A5—Paclitaxel—ovarian cancer	0.0409	0.0894	CbGbCtD
Enzalutamide—CYP2C8—Paclitaxel—ovarian cancer	0.0393	0.086	CbGbCtD
Enzalutamide—ABCB1—Vinorelbine—ovarian cancer	0.0378	0.0829	CbGbCtD
Enzalutamide—CYP2D6—Vinorelbine—ovarian cancer	0.0357	0.0781	CbGbCtD
Enzalutamide—CYP3A4—Topotecan—ovarian cancer	0.0322	0.0705	CbGbCtD
Enzalutamide—CYP3A5—Docetaxel—ovarian cancer	0.0295	0.0647	CbGbCtD
Enzalutamide—CYP2B6—Doxorubicin—ovarian cancer	0.0279	0.0612	CbGbCtD
Enzalutamide—CYP2C9—Paclitaxel—ovarian cancer	0.0274	0.06	CbGbCtD
Enzalutamide—ABCB1—Paclitaxel—ovarian cancer	0.0266	0.0582	CbGbCtD
Enzalutamide—CYP3A4—Vinorelbine—ovarian cancer	0.0227	0.0496	CbGbCtD
Enzalutamide—ABCB1—Docetaxel—ovarian cancer	0.0192	0.0421	CbGbCtD
Enzalutamide—CYP3A4—Paclitaxel—ovarian cancer	0.0159	0.0349	CbGbCtD
Enzalutamide—ABCB1—Doxorubicin—ovarian cancer	0.0143	0.0314	CbGbCtD
Enzalutamide—CYP2D6—Doxorubicin—ovarian cancer	0.0135	0.0296	CbGbCtD
Enzalutamide—CYP3A4—Docetaxel—ovarian cancer	0.0115	0.0252	CbGbCtD
Enzalutamide—CYP3A4—Doxorubicin—ovarian cancer	0.00859	0.0188	CbGbCtD
Enzalutamide—AR—oviduct—ovarian cancer	0.00311	0.14	CbGeAlD
Enzalutamide—AR—myometrium—ovarian cancer	0.000996	0.0448	CbGeAlD
Enzalutamide—Urethral disorder—Melphalan—ovarian cancer	0.000846	0.00617	CcSEcCtD
Enzalutamide—Pneumonia—Vinorelbine—ovarian cancer	0.000845	0.00616	CcSEcCtD
Enzalutamide—Infestation NOS—Vinorelbine—ovarian cancer	0.00084	0.00612	CcSEcCtD
Enzalutamide—Infestation—Vinorelbine—ovarian cancer	0.00084	0.00612	CcSEcCtD
Enzalutamide—Laryngitis—Epirubicin—ovarian cancer	0.000801	0.00584	CcSEcCtD
Enzalutamide—Angiopathy—Topotecan—ovarian cancer	0.0008	0.00583	CcSEcCtD
Enzalutamide—Injury—Paclitaxel—ovarian cancer	0.000798	0.00582	CcSEcCtD
Enzalutamide—Hot flush—Paclitaxel—ovarian cancer	0.000784	0.00571	CcSEcCtD
Enzalutamide—AR—epithelium—ovarian cancer	0.000782	0.0352	CbGeAlD
Enzalutamide—Menopausal symptoms—Paclitaxel—ovarian cancer	0.000777	0.00567	CcSEcCtD
Enzalutamide—AR—uterine cervix—ovarian cancer	0.000775	0.0349	CbGeAlD
Enzalutamide—Leukopenia—Chlorambucil—ovarian cancer	0.000772	0.00563	CcSEcCtD
Enzalutamide—Hypoaesthesia—Vinorelbine—ovarian cancer	0.00075	0.00547	CcSEcCtD
Enzalutamide—Convulsion—Chlorambucil—ovarian cancer	0.000747	0.00545	CcSEcCtD
Enzalutamide—Sepsis—Docetaxel—ovarian cancer	0.000743	0.00542	CcSEcCtD
Enzalutamide—Back pain—Topotecan—ovarian cancer	0.000742	0.00541	CcSEcCtD
Enzalutamide—Laryngitis—Doxorubicin—ovarian cancer	0.000741	0.0054	CcSEcCtD
Enzalutamide—Connective tissue disorder—Vinorelbine—ovarian cancer	0.000741	0.0054	CcSEcCtD
Enzalutamide—AR—decidua—ovarian cancer	0.000739	0.0332	CbGeAlD
Enzalutamide—AR—endometrium—ovarian cancer	0.000701	0.0315	CbGeAlD
Enzalutamide—Infection—Chlorambucil—ovarian cancer	0.000699	0.0051	CcSEcCtD
Enzalutamide—Thrombocytopenia—Chlorambucil—ovarian cancer	0.000689	0.00502	CcSEcCtD
Enzalutamide—Leukopenia—Topotecan—ovarian cancer	0.000687	0.00501	CcSEcCtD
Enzalutamide—Angiopathy—Vinorelbine—ovarian cancer	0.000684	0.00499	CcSEcCtD
Enzalutamide—Leukopenia—Melphalan—ovarian cancer	0.000673	0.0049	CcSEcCtD
Enzalutamide—Dry skin—Paclitaxel—ovarian cancer	0.000672	0.0049	CcSEcCtD
Enzalutamide—Hot flush—Docetaxel—ovarian cancer	0.000664	0.00484	CcSEcCtD
Enzalutamide—Menopausal symptoms—Docetaxel—ovarian cancer	0.000659	0.0048	CcSEcCtD
Enzalutamide—Nasopharyngitis—Paclitaxel—ovarian cancer	0.000656	0.00478	CcSEcCtD
Enzalutamide—Arthralgia—Topotecan—ovarian cancer	0.000653	0.00476	CcSEcCtD
Enzalutamide—Convulsion—Melphalan—ovarian cancer	0.000651	0.00475	CcSEcCtD
Enzalutamide—AR—gonad—ovarian cancer	0.00065	0.0293	CbGeAlD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.000649	0.00473	CcSEcCtD
Enzalutamide—Muscular weakness—Paclitaxel—ovarian cancer	0.000647	0.00472	CcSEcCtD
Enzalutamide—AR—uterus—ovarian cancer	0.000646	0.0291	CbGeAlD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.000635	0.00463	CcSEcCtD
Enzalutamide—Back pain—Vinorelbine—ovarian cancer	0.000635	0.00463	CcSEcCtD
Enzalutamide—Infection—Topotecan—ovarian cancer	0.000622	0.00454	CcSEcCtD
Enzalutamide—Nervous system disorder—Topotecan—ovarian cancer	0.000614	0.00448	CcSEcCtD
Enzalutamide—Thrombocytopenia—Topotecan—ovarian cancer	0.000613	0.00447	CcSEcCtD
Enzalutamide—Bronchitis—Paclitaxel—ovarian cancer	0.00061	0.00444	CcSEcCtD
Enzalutamide—Infection—Melphalan—ovarian cancer	0.000609	0.00444	CcSEcCtD
Enzalutamide—Skin disorder—Topotecan—ovarian cancer	0.000608	0.00444	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000607	0.00443	CcSEcCtD
Enzalutamide—Fatigue—Chlorambucil—ovarian cancer	0.000607	0.00442	CcSEcCtD
Enzalutamide—Thrombocytopenia—Melphalan—ovarian cancer	0.000601	0.00438	CcSEcCtD
Enzalutamide—Skin disorder—Melphalan—ovarian cancer	0.000596	0.00434	CcSEcCtD
Enzalutamide—Neutropenia—Paclitaxel—ovarian cancer	0.000593	0.00432	CcSEcCtD
Enzalutamide—Vertigo—Vinorelbine—ovarian cancer	0.00059	0.0043	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Paclitaxel—ovarian cancer	0.000589	0.00429	CcSEcCtD
Enzalutamide—Leukopenia—Vinorelbine—ovarian cancer	0.000588	0.00428	CcSEcCtD
Enzalutamide—Pollakiuria—Paclitaxel—ovarian cancer	0.000585	0.00427	CcSEcCtD
Enzalutamide—Musculoskeletal pain—Epirubicin—ovarian cancer	0.000585	0.00426	CcSEcCtD
Enzalutamide—AR—female reproductive system—ovarian cancer	0.000581	0.0261	CbGeAlD
Enzalutamide—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.000571	0.00416	CcSEcCtD
Enzalutamide—Dry skin—Docetaxel—ovarian cancer	0.00057	0.00415	CcSEcCtD
Enzalutamide—Pneumonia—Paclitaxel—ovarian cancer	0.000568	0.00414	CcSEcCtD
Enzalutamide—CYP2C8—endometrium—ovarian cancer	0.000567	0.0255	CbGeAlD
Enzalutamide—Hypertension—Vinorelbine—ovarian cancer	0.000567	0.00413	CcSEcCtD
Enzalutamide—CYP3A5—uterine cervix—ovarian cancer	0.000566	0.0255	CbGeAlD
Enzalutamide—Infestation NOS—Paclitaxel—ovarian cancer	0.000565	0.00412	CcSEcCtD
Enzalutamide—Infestation—Paclitaxel—ovarian cancer	0.000565	0.00412	CcSEcCtD
Enzalutamide—Paraesthesia—Topotecan—ovarian cancer	0.000562	0.0041	CcSEcCtD
Enzalutamide—Arthralgia—Vinorelbine—ovarian cancer	0.000559	0.00407	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.000559	0.00407	CcSEcCtD
Enzalutamide—Nasopharyngitis—Docetaxel—ovarian cancer	0.000556	0.00405	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000555	0.00405	CcSEcCtD
Enzalutamide—Paraesthesia—Melphalan—ovarian cancer	0.000551	0.00402	CcSEcCtD
Enzalutamide—Musculoskeletal pain—Doxorubicin—ovarian cancer	0.000541	0.00394	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000541	0.00394	CcSEcCtD
Enzalutamide—Fatigue—Topotecan—ovarian cancer	0.00054	0.00394	CcSEcCtD
Enzalutamide—ALB—testis—ovarian cancer	0.00054	0.0243	CbGeAlD
Enzalutamide—Haematuria—Paclitaxel—ovarian cancer	0.000539	0.00393	CcSEcCtD
Enzalutamide—Epistaxis—Paclitaxel—ovarian cancer	0.000533	0.00389	CcSEcCtD
Enzalutamide—Infection—Vinorelbine—ovarian cancer	0.000532	0.00388	CcSEcCtD
Enzalutamide—Sinusitis—Paclitaxel—ovarian cancer	0.00053	0.00387	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00053	0.00386	CcSEcCtD
Enzalutamide—Fatigue—Melphalan—ovarian cancer	0.000529	0.00386	CcSEcCtD
Enzalutamide—AR—female gonad—ovarian cancer	0.000529	0.0238	CbGeAlD
Enzalutamide—Nervous system disorder—Vinorelbine—ovarian cancer	0.000525	0.00383	CcSEcCtD
Enzalutamide—AR—vagina—ovarian cancer	0.000525	0.0236	CbGeAlD
Enzalutamide—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000525	0.00382	CcSEcCtD
Enzalutamide—Skin disorder—Vinorelbine—ovarian cancer	0.00052	0.00379	CcSEcCtD
Enzalutamide—Rhinitis—Paclitaxel—ovarian cancer	0.000509	0.00371	CcSEcCtD
Enzalutamide—Asthenia—Chlorambucil—ovarian cancer	0.000505	0.00368	CcSEcCtD
Enzalutamide—Hypoaesthesia—Paclitaxel—ovarian cancer	0.000505	0.00368	CcSEcCtD
Enzalutamide—Pharyngitis—Paclitaxel—ovarian cancer	0.000503	0.00367	CcSEcCtD
Enzalutamide—Neutropenia—Docetaxel—ovarian cancer	0.000502	0.00366	CcSEcCtD
Enzalutamide—Sepsis—Epirubicin—ovarian cancer	0.000501	0.00365	CcSEcCtD
Enzalutamide—Urinary tract disorder—Paclitaxel—ovarian cancer	0.000501	0.00365	CcSEcCtD
Enzalutamide—Oedema peripheral—Paclitaxel—ovarian cancer	0.0005	0.00364	CcSEcCtD
Enzalutamide—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000499	0.00363	CcSEcCtD
Enzalutamide—Pruritus—Chlorambucil—ovarian cancer	0.000498	0.00363	CcSEcCtD
Enzalutamide—Urethral disorder—Paclitaxel—ovarian cancer	0.000497	0.00363	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000488	0.00356	CcSEcCtD
Enzalutamide—CYP2C19—vagina—ovarian cancer	0.000487	0.0219	CbGeAlD
Enzalutamide—Pneumonia—Docetaxel—ovarian cancer	0.000482	0.00351	CcSEcCtD
Enzalutamide—Diarrhoea—Chlorambucil—ovarian cancer	0.000481	0.00351	CcSEcCtD
Enzalutamide—Paraesthesia—Vinorelbine—ovarian cancer	0.000481	0.00351	CcSEcCtD
Enzalutamide—Infestation NOS—Docetaxel—ovarian cancer	0.000479	0.00349	CcSEcCtD
Enzalutamide—Infestation—Docetaxel—ovarian cancer	0.000479	0.00349	CcSEcCtD
Enzalutamide—CYP2B6—gonad—ovarian cancer	0.000472	0.0212	CbGeAlD
Enzalutamide—CYP2C8—female reproductive system—ovarian cancer	0.00047	0.0211	CbGeAlD
Enzalutamide—AR—testis—ovarian cancer	0.000469	0.0211	CbGeAlD
Enzalutamide—Sepsis—Doxorubicin—ovarian cancer	0.000464	0.00338	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000463	0.00337	CcSEcCtD
Enzalutamide—Fatigue—Vinorelbine—ovarian cancer	0.000462	0.00337	CcSEcCtD
Enzalutamide—Angiopathy—Paclitaxel—ovarian cancer	0.00046	0.00336	CcSEcCtD
Enzalutamide—Epistaxis—Docetaxel—ovarian cancer	0.000452	0.00329	CcSEcCtD
Enzalutamide—Asthenia—Topotecan—ovarian cancer	0.000449	0.00328	CcSEcCtD
Enzalutamide—Hot flush—Epirubicin—ovarian cancer	0.000448	0.00327	CcSEcCtD
Enzalutamide—Mental disorder—Paclitaxel—ovarian cancer	0.000444	0.00324	CcSEcCtD
Enzalutamide—Menopausal symptoms—Epirubicin—ovarian cancer	0.000444	0.00324	CcSEcCtD
Enzalutamide—Pruritus—Topotecan—ovarian cancer	0.000443	0.00323	CcSEcCtD
Enzalutamide—Asthenia—Melphalan—ovarian cancer	0.00044	0.00321	CcSEcCtD
Enzalutamide—Pruritus—Melphalan—ovarian cancer	0.000434	0.00316	CcSEcCtD
Enzalutamide—Rhinitis—Docetaxel—ovarian cancer	0.000431	0.00314	CcSEcCtD
Enzalutamide—Diarrhoea—Topotecan—ovarian cancer	0.000429	0.00312	CcSEcCtD
Enzalutamide—Hypoaesthesia—Docetaxel—ovarian cancer	0.000428	0.00312	CcSEcCtD
Enzalutamide—Back pain—Paclitaxel—ovarian cancer	0.000427	0.00311	CcSEcCtD
Enzalutamide—Pharyngitis—Docetaxel—ovarian cancer	0.000427	0.00311	CcSEcCtD
Enzalutamide—CYP2C8—vagina—ovarian cancer	0.000425	0.0191	CbGeAlD
Enzalutamide—Urinary tract disorder—Docetaxel—ovarian cancer	0.000425	0.0031	CcSEcCtD
Enzalutamide—Oedema peripheral—Docetaxel—ovarian cancer	0.000424	0.00309	CcSEcCtD
Enzalutamide—Connective tissue disorder—Docetaxel—ovarian cancer	0.000423	0.00308	CcSEcCtD
Enzalutamide—Urethral disorder—Docetaxel—ovarian cancer	0.000421	0.00307	CcSEcCtD
Enzalutamide—CYP2B6—female reproductive system—ovarian cancer	0.000421	0.019	CbGeAlD
Enzalutamide—Diarrhoea—Melphalan—ovarian cancer	0.00042	0.00306	CcSEcCtD
Enzalutamide—CYP2C9—female reproductive system—ovarian cancer	0.000417	0.0188	CbGeAlD
Enzalutamide—Hot flush—Doxorubicin—ovarian cancer	0.000415	0.00302	CcSEcCtD
Enzalutamide—Dizziness—Topotecan—ovarian cancer	0.000414	0.00302	CcSEcCtD
Enzalutamide—Menopausal symptoms—Doxorubicin—ovarian cancer	0.000411	0.003	CcSEcCtD
Enzalutamide—Vertigo—Paclitaxel—ovarian cancer	0.000397	0.00289	CcSEcCtD
Enzalutamide—Leukopenia—Paclitaxel—ovarian cancer	0.000395	0.00288	CcSEcCtD
Enzalutamide—Headache—Topotecan—ovarian cancer	0.000392	0.00286	CcSEcCtD
Enzalutamide—ALB—lymph node—ovarian cancer	0.000391	0.0176	CbGeAlD
Enzalutamide—Angiopathy—Docetaxel—ovarian cancer	0.00039	0.00284	CcSEcCtD
Enzalutamide—ABCB1—myometrium—ovarian cancer	0.000386	0.0174	CbGeAlD
Enzalutamide—CYP3A5—female gonad—ovarian cancer	0.000386	0.0174	CbGeAlD
Enzalutamide—Asthenia—Vinorelbine—ovarian cancer	0.000384	0.0028	CcSEcCtD
Enzalutamide—Dry skin—Epirubicin—ovarian cancer	0.000384	0.0028	CcSEcCtD
Enzalutamide—CYP3A5—vagina—ovarian cancer	0.000383	0.0173	CbGeAlD
Enzalutamide—Convulsion—Paclitaxel—ovarian cancer	0.000383	0.00279	CcSEcCtD
Enzalutamide—Hypertension—Paclitaxel—ovarian cancer	0.000381	0.00278	CcSEcCtD
Enzalutamide—CYP2B6—vagina—ovarian cancer	0.000381	0.0171	CbGeAlD
Enzalutamide—CYP2C8—testis—ovarian cancer	0.000379	0.0171	CbGeAlD
Enzalutamide—Pruritus—Vinorelbine—ovarian cancer	0.000379	0.00276	CcSEcCtD
Enzalutamide—Mental disorder—Docetaxel—ovarian cancer	0.000377	0.00275	CcSEcCtD
Enzalutamide—Arthralgia—Paclitaxel—ovarian cancer	0.000376	0.00274	CcSEcCtD
Enzalutamide—Nasopharyngitis—Epirubicin—ovarian cancer	0.000375	0.00273	CcSEcCtD
Enzalutamide—Anxiety—Paclitaxel—ovarian cancer	0.000375	0.00273	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000373	0.00272	CcSEcCtD
Enzalutamide—ABCB1—embryo—ovarian cancer	0.000372	0.0167	CbGeAlD
Enzalutamide—Muscular weakness—Epirubicin—ovarian cancer	0.00037	0.0027	CcSEcCtD
Enzalutamide—Diarrhoea—Vinorelbine—ovarian cancer	0.000367	0.00267	CcSEcCtD
Enzalutamide—Back pain—Docetaxel—ovarian cancer	0.000362	0.00264	CcSEcCtD
Enzalutamide—Infection—Paclitaxel—ovarian cancer	0.000358	0.00261	CcSEcCtD
Enzalutamide—Dry skin—Doxorubicin—ovarian cancer	0.000356	0.00259	CcSEcCtD
Enzalutamide—Dizziness—Vinorelbine—ovarian cancer	0.000354	0.00258	CcSEcCtD
Enzalutamide—Nervous system disorder—Paclitaxel—ovarian cancer	0.000353	0.00258	CcSEcCtD
Enzalutamide—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000353	0.00257	CcSEcCtD
Enzalutamide—Skin disorder—Paclitaxel—ovarian cancer	0.00035	0.00255	CcSEcCtD
Enzalutamide—Bronchitis—Epirubicin—ovarian cancer	0.000348	0.00254	CcSEcCtD
Enzalutamide—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000347	0.00253	CcSEcCtD
Enzalutamide—Muscular weakness—Doxorubicin—ovarian cancer	0.000342	0.00249	CcSEcCtD
Enzalutamide—CYP2B6—testis—ovarian cancer	0.00034	0.0153	CbGeAlD
Enzalutamide—AR—lymph node—ovarian cancer	0.00034	0.0153	CbGeAlD
Enzalutamide—Neutropenia—Epirubicin—ovarian cancer	0.000339	0.00247	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000337	0.00246	CcSEcCtD
Enzalutamide—Headache—Vinorelbine—ovarian cancer	0.000336	0.00245	CcSEcCtD
Enzalutamide—Leukopenia—Docetaxel—ovarian cancer	0.000335	0.00244	CcSEcCtD
Enzalutamide—Pollakiuria—Epirubicin—ovarian cancer	0.000335	0.00244	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000328	0.00239	CcSEcCtD
Enzalutamide—Insomnia—Paclitaxel—ovarian cancer	0.000326	0.00238	CcSEcCtD
Enzalutamide—Pneumonia—Epirubicin—ovarian cancer	0.000325	0.00237	CcSEcCtD
Enzalutamide—Convulsion—Docetaxel—ovarian cancer	0.000324	0.00236	CcSEcCtD
Enzalutamide—Paraesthesia—Paclitaxel—ovarian cancer	0.000324	0.00236	CcSEcCtD
Enzalutamide—Hypertension—Docetaxel—ovarian cancer	0.000323	0.00236	CcSEcCtD
Enzalutamide—Infestation NOS—Epirubicin—ovarian cancer	0.000323	0.00236	CcSEcCtD
Enzalutamide—Infestation—Epirubicin—ovarian cancer	0.000323	0.00236	CcSEcCtD
Enzalutamide—Bronchitis—Doxorubicin—ovarian cancer	0.000322	0.00235	CcSEcCtD
Enzalutamide—Arthralgia—Docetaxel—ovarian cancer	0.000319	0.00232	CcSEcCtD
Enzalutamide—CYP3A4—female reproductive system—ovarian cancer	0.000318	0.0143	CbGeAlD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000316	0.00231	CcSEcCtD
Enzalutamide—Neutropenia—Doxorubicin—ovarian cancer	0.000314	0.00229	CcSEcCtD
Enzalutamide—CYP2D6—female reproductive system—ovarian cancer	0.000313	0.0141	CbGeAlD
Enzalutamide—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000312	0.00227	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000311	0.00227	CcSEcCtD
Enzalutamide—Fatigue—Paclitaxel—ovarian cancer	0.000311	0.00227	CcSEcCtD
Enzalutamide—Pollakiuria—Doxorubicin—ovarian cancer	0.00031	0.00226	CcSEcCtD
Enzalutamide—Haematuria—Epirubicin—ovarian cancer	0.000308	0.00225	CcSEcCtD
Enzalutamide—Epistaxis—Epirubicin—ovarian cancer	0.000305	0.00222	CcSEcCtD
Enzalutamide—Infection—Docetaxel—ovarian cancer	0.000303	0.00221	CcSEcCtD
Enzalutamide—ABCB1—epithelium—ovarian cancer	0.000303	0.0136	CbGeAlD
Enzalutamide—Sinusitis—Epirubicin—ovarian cancer	0.000303	0.00221	CcSEcCtD
Enzalutamide—Pneumonia—Doxorubicin—ovarian cancer	0.000301	0.00219	CcSEcCtD
Enzalutamide—ABCB1—uterine cervix—ovarian cancer	0.000301	0.0135	CbGeAlD
Enzalutamide—Nervous system disorder—Docetaxel—ovarian cancer	0.0003	0.00218	CcSEcCtD
Enzalutamide—Thrombocytopenia—Docetaxel—ovarian cancer	0.000299	0.00218	CcSEcCtD
Enzalutamide—Infestation NOS—Doxorubicin—ovarian cancer	0.000299	0.00218	CcSEcCtD
Enzalutamide—Infestation—Doxorubicin—ovarian cancer	0.000299	0.00218	CcSEcCtD
Enzalutamide—Skin disorder—Docetaxel—ovarian cancer	0.000297	0.00216	CcSEcCtD
Enzalutamide—Rhinitis—Epirubicin—ovarian cancer	0.000291	0.00212	CcSEcCtD
Enzalutamide—Hypoaesthesia—Epirubicin—ovarian cancer	0.000289	0.0021	CcSEcCtD
Enzalutamide—Pharyngitis—Epirubicin—ovarian cancer	0.000288	0.0021	CcSEcCtD
Enzalutamide—ABCB1—decidua—ovarian cancer	0.000286	0.0129	CbGeAlD
Enzalutamide—Urinary tract disorder—Epirubicin—ovarian cancer	0.000286	0.00209	CcSEcCtD
Enzalutamide—Oedema peripheral—Epirubicin—ovarian cancer	0.000286	0.00208	CcSEcCtD
Enzalutamide—Haematuria—Doxorubicin—ovarian cancer	0.000285	0.00208	CcSEcCtD
Enzalutamide—Connective tissue disorder—Epirubicin—ovarian cancer	0.000285	0.00208	CcSEcCtD
Enzalutamide—CYP2D6—female gonad—ovarian cancer	0.000285	0.0128	CbGeAlD
Enzalutamide—Urethral disorder—Epirubicin—ovarian cancer	0.000284	0.00207	CcSEcCtD
Enzalutamide—Epistaxis—Doxorubicin—ovarian cancer	0.000282	0.00206	CcSEcCtD
Enzalutamide—Sinusitis—Doxorubicin—ovarian cancer	0.00028	0.00204	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000278	0.00203	CcSEcCtD
Enzalutamide—Insomnia—Docetaxel—ovarian cancer	0.000276	0.00201	CcSEcCtD
Enzalutamide—Paraesthesia—Docetaxel—ovarian cancer	0.000274	0.002	CcSEcCtD
Enzalutamide—ABCB1—endometrium—ovarian cancer	0.000272	0.0122	CbGeAlD
Enzalutamide—Rhinitis—Doxorubicin—ovarian cancer	0.000269	0.00196	CcSEcCtD
Enzalutamide—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000267	0.00195	CcSEcCtD
Enzalutamide—Pharyngitis—Doxorubicin—ovarian cancer	0.000266	0.00194	CcSEcCtD
Enzalutamide—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000265	0.00193	CcSEcCtD
Enzalutamide—Oedema peripheral—Doxorubicin—ovarian cancer	0.000264	0.00193	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000264	0.00192	CcSEcCtD
Enzalutamide—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000264	0.00192	CcSEcCtD
Enzalutamide—Fatigue—Docetaxel—ovarian cancer	0.000263	0.00192	CcSEcCtD
Enzalutamide—Angiopathy—Epirubicin—ovarian cancer	0.000263	0.00192	CcSEcCtD
Enzalutamide—Urethral disorder—Doxorubicin—ovarian cancer	0.000263	0.00192	CcSEcCtD
Enzalutamide—Asthenia—Paclitaxel—ovarian cancer	0.000259	0.00189	CcSEcCtD
Enzalutamide—Pruritus—Paclitaxel—ovarian cancer	0.000255	0.00186	CcSEcCtD
Enzalutamide—Mental disorder—Epirubicin—ovarian cancer	0.000254	0.00185	CcSEcCtD
Enzalutamide—CYP2D6—testis—ovarian cancer	0.000253	0.0114	CbGeAlD
Enzalutamide—ABCB1—gonad—ovarian cancer	0.000252	0.0113	CbGeAlD
Enzalutamide—ABCB1—uterus—ovarian cancer	0.000251	0.0113	CbGeAlD
Enzalutamide—Diarrhoea—Paclitaxel—ovarian cancer	0.000247	0.0018	CcSEcCtD
Enzalutamide—Back pain—Epirubicin—ovarian cancer	0.000244	0.00178	CcSEcCtD
Enzalutamide—Angiopathy—Doxorubicin—ovarian cancer	0.000243	0.00177	CcSEcCtD
Enzalutamide—Dizziness—Paclitaxel—ovarian cancer	0.000238	0.00174	CcSEcCtD
Enzalutamide—Mental disorder—Doxorubicin—ovarian cancer	0.000235	0.00171	CcSEcCtD
Enzalutamide—Vertigo—Epirubicin—ovarian cancer	0.000227	0.00165	CcSEcCtD
Enzalutamide—Leukopenia—Epirubicin—ovarian cancer	0.000226	0.00165	CcSEcCtD
Enzalutamide—Back pain—Doxorubicin—ovarian cancer	0.000226	0.00165	CcSEcCtD
Enzalutamide—Headache—Paclitaxel—ovarian cancer	0.000226	0.00165	CcSEcCtD
Enzalutamide—ABCB1—female reproductive system—ovarian cancer	0.000225	0.0101	CbGeAlD
Enzalutamide—Asthenia—Docetaxel—ovarian cancer	0.000219	0.0016	CcSEcCtD
Enzalutamide—Convulsion—Epirubicin—ovarian cancer	0.000219	0.00159	CcSEcCtD
Enzalutamide—Hypertension—Epirubicin—ovarian cancer	0.000218	0.00159	CcSEcCtD
Enzalutamide—Pruritus—Docetaxel—ovarian cancer	0.000216	0.00158	CcSEcCtD
Enzalutamide—Arthralgia—Epirubicin—ovarian cancer	0.000215	0.00157	CcSEcCtD
Enzalutamide—Anxiety—Epirubicin—ovarian cancer	0.000214	0.00156	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000213	0.00156	CcSEcCtD
Enzalutamide—ABCB1—bone marrow—ovarian cancer	0.000213	0.00957	CbGeAlD
Enzalutamide—Vertigo—Doxorubicin—ovarian cancer	0.00021	0.00153	CcSEcCtD
Enzalutamide—Leukopenia—Doxorubicin—ovarian cancer	0.000209	0.00152	CcSEcCtD
Enzalutamide—Diarrhoea—Docetaxel—ovarian cancer	0.000209	0.00152	CcSEcCtD
Enzalutamide—ABCB1—female gonad—ovarian cancer	0.000205	0.00922	CbGeAlD
Enzalutamide—Infection—Epirubicin—ovarian cancer	0.000205	0.00149	CcSEcCtD
Enzalutamide—ABCB1—vagina—ovarian cancer	0.000204	0.00916	CbGeAlD
Enzalutamide—Convulsion—Doxorubicin—ovarian cancer	0.000202	0.00148	CcSEcCtD
Enzalutamide—Nervous system disorder—Epirubicin—ovarian cancer	0.000202	0.00147	CcSEcCtD
Enzalutamide—Dizziness—Docetaxel—ovarian cancer	0.000202	0.00147	CcSEcCtD
Enzalutamide—Thrombocytopenia—Epirubicin—ovarian cancer	0.000202	0.00147	CcSEcCtD
Enzalutamide—Hypertension—Doxorubicin—ovarian cancer	0.000202	0.00147	CcSEcCtD
Enzalutamide—Skin disorder—Epirubicin—ovarian cancer	0.0002	0.00146	CcSEcCtD
Enzalutamide—Arthralgia—Doxorubicin—ovarian cancer	0.000199	0.00145	CcSEcCtD
Enzalutamide—Anxiety—Doxorubicin—ovarian cancer	0.000198	0.00144	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000198	0.00144	CcSEcCtD
Enzalutamide—Headache—Docetaxel—ovarian cancer	0.000191	0.0014	CcSEcCtD
Enzalutamide—Infection—Doxorubicin—ovarian cancer	0.000189	0.00138	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000188	0.00137	CcSEcCtD
Enzalutamide—Nervous system disorder—Doxorubicin—ovarian cancer	0.000187	0.00136	CcSEcCtD
Enzalutamide—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000187	0.00136	CcSEcCtD
Enzalutamide—Insomnia—Epirubicin—ovarian cancer	0.000186	0.00136	CcSEcCtD
Enzalutamide—Skin disorder—Doxorubicin—ovarian cancer	0.000185	0.00135	CcSEcCtD
Enzalutamide—Paraesthesia—Epirubicin—ovarian cancer	0.000185	0.00135	CcSEcCtD
Enzalutamide—ABCB1—testis—ovarian cancer	0.000182	0.00818	CbGeAlD
Enzalutamide—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000178	0.0013	CcSEcCtD
Enzalutamide—Fatigue—Epirubicin—ovarian cancer	0.000178	0.0013	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000174	0.00127	CcSEcCtD
Enzalutamide—Insomnia—Doxorubicin—ovarian cancer	0.000172	0.00126	CcSEcCtD
Enzalutamide—Paraesthesia—Doxorubicin—ovarian cancer	0.000171	0.00125	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000165	0.0012	CcSEcCtD
Enzalutamide—Fatigue—Doxorubicin—ovarian cancer	0.000164	0.0012	CcSEcCtD
Enzalutamide—Asthenia—Epirubicin—ovarian cancer	0.000148	0.00108	CcSEcCtD
Enzalutamide—Pruritus—Epirubicin—ovarian cancer	0.000146	0.00106	CcSEcCtD
Enzalutamide—Diarrhoea—Epirubicin—ovarian cancer	0.000141	0.00103	CcSEcCtD
Enzalutamide—Asthenia—Doxorubicin—ovarian cancer	0.000137	0.000997	CcSEcCtD
Enzalutamide—Dizziness—Epirubicin—ovarian cancer	0.000136	0.000993	CcSEcCtD
Enzalutamide—Pruritus—Doxorubicin—ovarian cancer	0.000135	0.000983	CcSEcCtD
Enzalutamide—ABCB1—lymph node—ovarian cancer	0.000132	0.00593	CbGeAlD
Enzalutamide—Diarrhoea—Doxorubicin—ovarian cancer	0.00013	0.000951	CcSEcCtD
Enzalutamide—Headache—Epirubicin—ovarian cancer	0.000129	0.000941	CcSEcCtD
Enzalutamide—Dizziness—Doxorubicin—ovarian cancer	0.000126	0.000919	CcSEcCtD
Enzalutamide—Headache—Doxorubicin—ovarian cancer	0.000119	0.000871	CcSEcCtD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	3.06e-05	0.000739	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CYTB—ovarian cancer	2.99e-05	0.000721	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	2.97e-05	0.000717	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CYTB—ovarian cancer	2.92e-05	0.000705	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.86e-05	0.000692	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	2.73e-05	0.00066	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—PIK3CD—ovarian cancer	2.73e-05	0.00066	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.71e-05	0.000655	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	2.71e-05	0.000654	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.7e-05	0.000651	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—IL6—ovarian cancer	2.68e-05	0.000648	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—PPP2R1A—ovarian cancer	2.68e-05	0.000648	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—BRIP1—ovarian cancer	2.61e-05	0.00063	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PPP1CC—ovarian cancer	2.61e-05	0.00063	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—BRIP1—ovarian cancer	2.55e-05	0.000616	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PPP1CC—ovarian cancer	2.55e-05	0.000616	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CYTB—ovarian cancer	2.53e-05	0.00061	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.52e-05	0.000609	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CYTB—ovarian cancer	2.51e-05	0.000607	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.47e-05	0.000597	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.46e-05	0.000593	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.44e-05	0.000588	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.42e-05	0.000585	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—SOD1—ovarian cancer	2.4e-05	0.000581	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—PPP2R1A—ovarian cancer	2.39e-05	0.000578	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	2.38e-05	0.000575	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	2.38e-05	0.000574	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CYTB—ovarian cancer	2.26e-05	0.000545	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.21e-05	0.000534	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PPP1CC—ovarian cancer	2.21e-05	0.000534	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—BRIP1—ovarian cancer	2.21e-05	0.000534	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.21e-05	0.000533	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.2e-05	0.000532	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CYTB—ovarian cancer	2.2e-05	0.000532	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	2.2e-05	0.000531	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PPP1CC—ovarian cancer	2.2e-05	0.00053	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—BRIP1—ovarian cancer	2.2e-05	0.00053	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—IL2—ovarian cancer	2.19e-05	0.000528	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	2.16e-05	0.000521	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.13e-05	0.000515	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NME2—ovarian cancer	2.11e-05	0.000508	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2.1e-05	0.000507	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	2.08e-05	0.000502	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CYTB—ovarian cancer	2.07e-05	0.000501	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CYTB—ovarian cancer	2.06e-05	0.000497	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—MYC—ovarian cancer	2.05e-05	0.000495	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	2.03e-05	0.000489	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.01e-05	0.000486	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—BRIP1—ovarian cancer	1.97e-05	0.000476	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PPP1CC—ovarian cancer	1.97e-05	0.000476	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PPP1CC—ovarian cancer	1.92e-05	0.000465	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—BRIP1—ovarian cancer	1.92e-05	0.000465	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.92e-05	0.000464	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—ESR1—ovarian cancer	1.9e-05	0.000459	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	1.86e-05	0.000449	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	1.83e-05	0.000442	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PPP1CC—ovarian cancer	1.81e-05	0.000438	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—BRIP1—ovarian cancer	1.81e-05	0.000438	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PPP1CC—ovarian cancer	1.8e-05	0.000434	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—BRIP1—ovarian cancer	1.8e-05	0.000434	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—CAV1—ovarian cancer	1.76e-05	0.000425	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	1.76e-05	0.000424	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—YAP1—ovarian cancer	1.75e-05	0.000423	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	1.73e-05	0.000418	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—YAP1—ovarian cancer	1.71e-05	0.000413	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	1.68e-05	0.000407	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	1.67e-05	0.000404	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	1.65e-05	0.000398	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	1.65e-05	0.000398	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.61e-05	0.000389	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—PIK3CG—ovarian cancer	1.6e-05	0.000387	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.6e-05	0.000387	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.56e-05	0.000376	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—YAP1—ovarian cancer	1.48e-05	0.000358	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—YAP1—ovarian cancer	1.47e-05	0.000356	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.47e-05	0.000354	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.46e-05	0.000352	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	1.45e-05	0.00035	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.44e-05	0.000347	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.43e-05	0.000345	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—FASN—ovarian cancer	1.43e-05	0.000345	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—PIK3CD—ovarian cancer	1.41e-05	0.00034	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—SLC5A5—ovarian cancer	1.4e-05	0.000339	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—FASN—ovarian cancer	1.39e-05	0.000337	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.38e-05	0.000334	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—SLC5A5—ovarian cancer	1.37e-05	0.000331	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CYTB—ovarian cancer	1.36e-05	0.000328	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—SLC2A1—ovarian cancer	1.36e-05	0.000327	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—SLC2A1—ovarian cancer	1.32e-05	0.00032	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—YAP1—ovarian cancer	1.32e-05	0.000319	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.31e-05	0.000316	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.31e-05	0.000316	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CYP1B1—ovarian cancer	1.3e-05	0.000314	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—YAP1—ovarian cancer	1.29e-05	0.000312	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.29e-05	0.000311	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.28e-05	0.00031	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CYP1B1—ovarian cancer	1.27e-05	0.000307	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—PIK3CB—ovarian cancer	1.23e-05	0.000296	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—YAP1—ovarian cancer	1.22e-05	0.000294	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—FASN—ovarian cancer	1.21e-05	0.000292	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—YAP1—ovarian cancer	1.21e-05	0.000291	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—FASN—ovarian cancer	1.2e-05	0.00029	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.19e-05	0.000288	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—SLC5A5—ovarian cancer	1.19e-05	0.000287	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.19e-05	0.000286	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.19e-05	0.000286	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	1.19e-05	0.000286	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—SLC5A5—ovarian cancer	1.18e-05	0.000285	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.17e-05	0.000282	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PPP2R1A—ovarian cancer	1.15e-05	0.000278	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.15e-05	0.000278	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—SLC2A1—ovarian cancer	1.15e-05	0.000277	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—SLC2A1—ovarian cancer	1.14e-05	0.000276	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—IL2—ovarian cancer	1.13e-05	0.000272	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	1.13e-05	0.000272	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.12e-05	0.000271	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.12e-05	0.00027	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CYP1B1—ovarian cancer	1.1e-05	0.000266	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CYP1B1—ovarian cancer	1.09e-05	0.000264	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—FASN—ovarian cancer	1.08e-05	0.00026	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—ABCB1—ovarian cancer	1.07e-05	0.000258	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—SLC5A5—ovarian cancer	1.06e-05	0.000256	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—FASN—ovarian cancer	1.05e-05	0.000254	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—TYMS—ovarian cancer	1.05e-05	0.000254	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.05e-05	0.000253	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—ABCB1—ovarian cancer	1.05e-05	0.000253	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—SLC5A5—ovarian cancer	1.04e-05	0.00025	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—TYMS—ovarian cancer	1.03e-05	0.000248	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—SLC2A1—ovarian cancer	1.02e-05	0.000247	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—MAPK3—ovarian cancer	1.02e-05	0.000245	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1e-05	0.000242	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—SLC2A1—ovarian cancer	1e-05	0.000241	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—FASN—ovarian cancer	9.92e-06	0.000239	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—MYC—ovarian cancer	9.88e-06	0.000239	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—FASN—ovarian cancer	9.83e-06	0.000237	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CYP1B1—ovarian cancer	9.82e-06	0.000237	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	9.76e-06	0.000236	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—SLC5A5—ovarian cancer	9.75e-06	0.000236	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.71e-06	0.000234	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PPP2R1A—ovarian cancer	9.7e-06	0.000234	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—SLC5A5—ovarian cancer	9.67e-06	0.000234	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.65e-06	0.000233	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CYP1B1—ovarian cancer	9.58e-06	0.000231	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—VEGFA—ovarian cancer	9.58e-06	0.000231	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—NRAS—ovarian cancer	9.46e-06	0.000228	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—SLC2A1—ovarian cancer	9.42e-06	0.000227	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—SLC2A1—ovarian cancer	9.34e-06	0.000226	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	9.14e-06	0.000221	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—MAPK3—ovarian cancer	9.06e-06	0.000219	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—ABCB1—ovarian cancer	9.06e-06	0.000219	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CYP1B1—ovarian cancer	9.03e-06	0.000218	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—ABCB1—ovarian cancer	9.01e-06	0.000218	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CYP1B1—ovarian cancer	8.95e-06	0.000216	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—TYMS—ovarian cancer	8.9e-06	0.000215	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—TYMS—ovarian cancer	8.85e-06	0.000214	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	8.71e-06	0.00021	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.67e-06	0.000209	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—MAPK1—ovarian cancer	8.62e-06	0.000208	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PPP2R1A—ovarian cancer	8.5e-06	0.000205	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CAV1—ovarian cancer	8.47e-06	0.000205	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CAV1—ovarian cancer	8.28e-06	0.0002	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—KRAS—ovarian cancer	8.14e-06	0.000197	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—ABCB1—ovarian cancer	8.09e-06	0.000195	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	8.01e-06	0.000193	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—YAP1—ovarian cancer	7.95e-06	0.000192	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—TYMS—ovarian cancer	7.94e-06	0.000192	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	7.94e-06	0.000192	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.9e-06	0.000191	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—TYMS—ovarian cancer	7.75e-06	0.000187	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PIK3CG—ovarian cancer	7.71e-06	0.000186	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PIK3CG—ovarian cancer	7.54e-06	0.000182	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—PIK3CA—ovarian cancer	7.48e-06	0.000181	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—ABCB1—ovarian cancer	7.44e-06	0.00018	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—ABCB1—ovarian cancer	7.37e-06	0.000178	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—TYMS—ovarian cancer	7.3e-06	0.000176	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—TYMS—ovarian cancer	7.24e-06	0.000175	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—TP53—ovarian cancer	7.24e-06	0.000175	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CAV1—ovarian cancer	7.17e-06	0.000173	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CAV1—ovarian cancer	7.13e-06	0.000172	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—HRAS—ovarian cancer	6.92e-06	0.000167	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—AKT1—ovarian cancer	6.85e-06	0.000165	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.85e-06	0.000165	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.81e-06	0.000164	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PIK3CD—ovarian cancer	6.78e-06	0.000164	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PIK3CD—ovarian cancer	6.63e-06	0.00016	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PIK3CG—ovarian cancer	6.53e-06	0.000158	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PIK3CG—ovarian cancer	6.49e-06	0.000157	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—FASN—ovarian cancer	6.48e-06	0.000157	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CAV1—ovarian cancer	6.4e-06	0.000155	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—SLC5A5—ovarian cancer	6.38e-06	0.000154	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CAV1—ovarian cancer	6.25e-06	0.000151	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—SLC2A1—ovarian cancer	6.16e-06	0.000149	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.11e-06	0.000148	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—AKT1—ovarian cancer	6.11e-06	0.000148	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PIK3CB—ovarian cancer	5.91e-06	0.000143	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CYP1B1—ovarian cancer	5.9e-06	0.000143	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CAV1—ovarian cancer	5.89e-06	0.000142	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CAV1—ovarian cancer	5.83e-06	0.000141	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PIK3CG—ovarian cancer	5.83e-06	0.000141	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PIK3CB—ovarian cancer	5.78e-06	0.00014	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PIK3CD—ovarian cancer	5.74e-06	0.000139	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PIK3CD—ovarian cancer	5.71e-06	0.000138	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PIK3CG—ovarian cancer	5.69e-06	0.000137	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.57e-06	0.000135	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PIK3CG—ovarian cancer	5.36e-06	0.000129	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PIK3CG—ovarian cancer	5.31e-06	0.000128	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	5.24e-06	0.000126	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PIK3CD—ovarian cancer	5.12e-06	0.000124	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PTEN—ovarian cancer	5.11e-06	0.000123	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PIK3CB—ovarian cancer	5e-06	0.000121	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PIK3CD—ovarian cancer	5e-06	0.000121	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PTEN—ovarian cancer	4.99e-06	0.000121	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PIK3CB—ovarian cancer	4.98e-06	0.00012	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ABCB1—ovarian cancer	4.86e-06	0.000117	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—TYMS—ovarian cancer	4.78e-06	0.000115	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PIK3CD—ovarian cancer	4.71e-06	0.000114	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PIK3CD—ovarian cancer	4.67e-06	0.000113	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PIK3CB—ovarian cancer	4.47e-06	0.000108	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PIK3CB—ovarian cancer	4.36e-06	0.000105	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PTEN—ovarian cancer	4.32e-06	0.000104	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PTEN—ovarian cancer	4.3e-06	0.000104	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4.11e-06	9.92e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PIK3CB—ovarian cancer	4.07e-06	9.84e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PTEN—ovarian cancer	3.86e-06	9.32e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CAV1—ovarian cancer	3.85e-06	9.29e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PTEN—ovarian cancer	3.77e-06	9.1e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PIK3CA—ovarian cancer	3.6e-06	8.7e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PTEN—ovarian cancer	3.55e-06	8.57e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PIK3CA—ovarian cancer	3.52e-06	8.51e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PTEN—ovarian cancer	3.52e-06	8.5e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.51e-06	8.47e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.08e-06	7.44e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PIK3CA—ovarian cancer	3.05e-06	7.37e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PIK3CA—ovarian cancer	3.03e-06	7.32e-05	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—AKT1—ovarian cancer	2.94e-06	7.11e-05	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—AKT1—ovarian cancer	2.88e-06	6.95e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PIK3CA—ovarian cancer	2.72e-06	6.58e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.69e-06	6.49e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.66e-06	6.42e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.5e-06	6.05e-05	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—AKT1—ovarian cancer	2.49e-06	6.02e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PIK3CA—ovarian cancer	2.48e-06	6e-05	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—AKT1—ovarian cancer	2.48e-06	5.98e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PTEN—ovarian cancer	2.32e-06	5.6e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—AKT1—ovarian cancer	2.22e-06	5.37e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—AKT1—ovarian cancer	2.17e-06	5.24e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—AKT1—ovarian cancer	2.05e-06	4.94e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—AKT1—ovarian cancer	2.03e-06	4.9e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.64e-06	3.95e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—AKT1—ovarian cancer	1.34e-06	3.23e-05	CbGpPWpGaD
